Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Drug Discrimination

Most CNS drugs produce a pharmacologically specific interoceptive cue in rats that they can use to differentiate between the training drug and vehicle. Drug discrimination testing using abused drugs as the training cues is used to investigate whether novel CNS-active compounds produce similar psychoactive effects and is a core part of the regulatory non-clinical abuse potential package. Test drugs that generalise to the comparator drug are likely to produce similar psychoactive effects in humans. All drug discrimination studies can be performed to GLP to adhere to regulatory requirements.

Drug discrimination can be established across a broad range of CNS active mechanisms

A wide range of drug cues have been validated including:

Stimulants

Opioids

CNS depressants

NMDA antagonists

MDMA and other entactogens

Hallucinogens

Benzodiazepines and non-benzodiazepine GABAergics

Cannabinoids

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.